AIM: To analyse the role of two common polymorphisms in genes coding for histamine metabolising enzymes as it relates to the risk to develop ulcerative colitis (UC) and the clinical course of these patients. METHODS: A cohort of 229 unrelated patients with UC recruited from a single centre and 261 healthy volunteers were analysed for the presence of Thr105Ile and His645Asp amino acid substitutions at histamine N-methyltransferase (HNMT) and diamine oxidase (ABP1) enzymes, respectively, by amplification-restriction procedures. All patients were phenotyped and followed up for at least 2 years (mean time 11 years). RESULTS: There were no significant differences in the distribution of ABP1 alleles between ulcerative colitis patients and healthy individuals [OR (95% CI) for variant alleles=1.22 (0.91-1.61)]. However, mutated ABP1 alleles were present with higher frequency among the 58 patients that required immunosuppressive drugs [OR (95 % CI) for carriers of mutated alleles 2.41 (1.21-4.83; P=0.006)], with a significant gene-dose effect (P=0.0038). In agreement with the predominant role of ABP1 versus HNMT on local histamine metabolism in human bowel, the frequencies for carriers of HNMT genotypes or mutated alleles were similar among patients, regardless clinical evolution, and control individuals. CONCLUSION: The His645Asp polymorphism of the histamine metabolising enzyme ABP1 is related to severity of ulcerative colitis.
AIM: To analyse the role of two common polymorphisms in genes coding for histamine metabolising enzymes as it relates to the risk to develop ulcerative colitis (UC) and the clinical course of these patients. METHODS: A cohort of 229 unrelated patients with UC recruited from a single centre and 261 healthy volunteers were analysed for the presence of Thr105Ile and His645Asp amino acid substitutions at histamine N-methyltransferase (HNMT) and diamine oxidase (ABP1) enzymes, respectively, by amplification-restriction procedures. All patients were phenotyped and followed up for at least 2 years (mean time 11 years). RESULTS: There were no significant differences in the distribution of ABP1 alleles between ulcerative colitispatients and healthy individuals [OR (95% CI) for variant alleles=1.22 (0.91-1.61)]. However, mutated ABP1 alleles were present with higher frequency among the 58 patients that required immunosuppressive drugs [OR (95 % CI) for carriers of mutated alleles 2.41 (1.21-4.83; P=0.006)], with a significant gene-dose effect (P=0.0038). In agreement with the predominant role of ABP1 versus HNMT on local histamine metabolism in human bowel, the frequencies for carriers of HNMT genotypes or mutated alleles were similar among patients, regardless clinical evolution, and control individuals. CONCLUSION: The His645Asp polymorphism of the histamine metabolising enzyme ABP1 is related to severity of ulcerative colitis.
Authors: S Winterkamp; M Weidenhiller; P Otte; J Stolper; D Schwab; E G Hahn; M Raithel Journal: Am J Gastroenterol Date: 2002-12 Impact factor: 10.864
Authors: C V Preuss; T C Wood; C L Szumlanski; R B Raftogianis; D M Otterness; B Girard; M C Scott; R M Weinshilboum Journal: Mol Pharmacol Date: 1998-04 Impact factor: 4.436
Authors: K G Becker; R M Simon; J E Bailey-Wilson; B Freidlin; W E Biddison; H F McFarland; J M Trent Journal: Proc Natl Acad Sci U S A Date: 1998-08-18 Impact factor: 11.205
Authors: Steven R Brant; Carolien I M Panhuysen; Dan Nicolae; Deepthi M Reddy; Denise K Bonen; Reda Karaliukas; Leilei Zhang; Eric Swanson; Lisa W Datta; Thomas Moran; Geoffrey Ravenhill; Richard H Duerr; Jean-Paul Achkar; Amir S Karban; Judy H Cho Journal: Am J Hum Genet Date: 2003-11-07 Impact factor: 11.025
Authors: Carmen Martínez; José A Molina; Hortensia Alonso-Navarro; Félix J Jiménez-Jiménez; José A G Agúndez; Elena García-Martín Journal: BMC Neurol Date: 2010-08-19 Impact factor: 2.474
Authors: Gemma Amo; José A Cornejo-García; Jesus M García-Menaya; Concepcion Cordobes; M J Torres; Gara Esguevillas; Cristobalina Mayorga; Carmen Martinez; Natalia Blanca-Lopez; Gabriela Canto; Alfonso Ramos; Miguel Blanca; José A G Agúndez; Elena García-Martín Journal: Front Pharmacol Date: 2016-09-29 Impact factor: 5.810
Authors: J B Wechsler; A Szabo; C L Hsu; R A Krier-Burris; H A Schroeder; M Y Wang; R G Carter; T E Velez; L M Aguiniga; J B Brown; M L Miller; B K Wershil; T A Barrett; P J Bryce Journal: Mucosal Immunol Date: 2018-01-24 Impact factor: 7.313
Authors: José A G Agúndez; Pedro Ayuso; José A Cornejo-García; Miguel Blanca; María J Torres; Inmaculada Doña; María Salas; Natalia Blanca-López; Gabriela Canto; Carmen Rondon; Paloma Campo; José J Laguna; Javier Fernández; Carmen Martínez; Elena García-Martín Journal: PLoS One Date: 2012-11-12 Impact factor: 3.240